Cargando…

Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis

IMPORTANCE: Placebo responses in the treatment of erectile dysfunction (ED) are poorly described in the literature to date. OBJECTIVE: To quantify the association of placebo with ED outcomes among men enrolled in placebo-controlled, phosphodiesterase 5 inhibitor (PDE5I) trials. DATA SOURCES: For thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stridh, Alexander, Pontén, Moa, Arver, Stefan, Kirsch, Irving, Abé, Christoph, Jensen, Karin B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084170/ https://www.ncbi.nlm.nih.gov/pubmed/32196105 http://dx.doi.org/10.1001/jamanetworkopen.2020.1423

Ejemplares similares

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Association of Diet With Erectile Dysfunction Among Men in the Health Professionals Follow-up Study
por: Bauer, Scott R., et al.
Publicado: (2020)

Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study
por: Rosenberg, M T, et al.
Publicado: (2009)

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
por: Carvalheira, Ana, et al.
Publicado: (2014)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain: A Systematic Review and Meta-analysis
por: Gedin, Filip, et al.
Publicado: (2022)

Shaping placebo analgesic responses on the Internet: a randomized experimental trial
por: Pontén, Moa, et al.
Publicado: (2019)

Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis
por: Zhu, Jun, et al.
Publicado: (2020)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction
por: Shabsigh, Ridwan, et al.
Publicado: (2010)

The triad of erectile dysfunction, hypogonadism and the metabolic syndrome
por: Shabsigh, R, et al.
Publicado: (2008)

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
por: Lee, Lulu K, et al.
Publicado: (2016)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Oral L-citrulline and Transresveratrol Supplementation Improves Erectile Function in Men With Phosphodiesterase 5 Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study
por: Shirai, Masato, et al.
Publicado: (2018)

Deterioration of heart rate recovery index in patients with erectile dysfunction
por: Ulucan, Şeref, et al.
Publicado: (2016)

Naltrexone during pain conditioning: A double-blind placebo-controlled experimental trial
por: Pontén, Moa, et al.
Publicado: (2020)

Heart Rate Variability in Men with Erectile dysfunction
por: Lee, Ji Yong, et al.
Publicado: (2011)

Testosterone Deficiency with Erectile Dysfunction in Mongolian Men
por: Naidan, Nansalmaa, et al.
Publicado: (2013)

A syndrome of erectile dysfunction in young men?
por: Reed-Maldonado, Amanda B., et al.
Publicado: (2016)

Evaluation of young men with organic erectile dysfunction
por: Papagiannopoulos, Dimitri, et al.
Publicado: (2015)

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
por: Kim, Su Jin, et al.
Publicado: (2016)

Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction
por: Wang, Jian, et al.
Publicado: (2021)

The effectiveness of psychological interventions alone, or in combination with phosphodiesterase-5 inhibitors, for the treatment of erectile dysfunction:A systematic review
por: Atallah, Sandrine, et al.
Publicado: (2021)

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction
por: Cota, Jason M., et al.
Publicado: (2021)

Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial
por: Landgren, Valdemar, et al.
Publicado: (2020)

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy
por: Bai, Wen-Jun, et al.
Publicado: (2015)

Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil
por: Dietz, Ulrich, et al.
Publicado: (2003)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

Efficacy of tadalafil on improvement of men with erectile dysfunction caused by COVID-19: A randomized placebo-controlled trial
por: Shamohammadi, Iman, et al.
Publicado: (2022)

Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
por: Raheem, Amr Abdel, et al.
Publicado: (2009)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
por: Yuan, Jin-Qiu, et al.
Publicado: (2016)

Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis
por: Yang, Jie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q0d9sqrruhbdsg27ovhlj2ot87